Search Results - "Botsen, Damien"

Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients by Callon, Sidonie, Brugel, Mathias, Botsen, Damien, Royer, Bernard, Slimano, Florian, Feliu, Catherine, Gozalo, Claire, Konecki, Céline, Devie, Bruno, Carlier, Claire, Daire, Viktor, Laurés, Nicolas, Perrier, Marine, Djerada, Zoubir, Bouché, Olivier

“…Background: Dihydropyrimidine dehydrogenase (DPD) deficiency screening is a pre-therapeutic standard to prevent severe fluoropyrimidine-related toxicity…”
Get full text

Dynapenia in digestive cancer outpatients: association with markers of functional and nutritional status (the FIGHTDIGO study) by Perrier, Marine, Ordan, Marie-Amelie, Barbe, Coralie, Mazza, Camille, Botsen, Damien, Moreau, Johanna, Renard, Yohann, Brasseur, Mathilde, Tailliere, Barbara, Regnault, Philippe, Bertin, Eric, Bouche, Olivier

“…Background The FIGHTDIGO study determined the feasibility and acceptability of handgrip strength (HGS) measurement in digestive cancer outpatients. Purpose To…”
Get full text

Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX) by Martin, Pierre, Botsen, Damien, Brugel, Mathias, Bertin, Eric, Carlier, Claire, Mahmoudi, Rachid, Slimano, Florian, Perrier, Marine, Bouché, Olivier

“…In the FIGHTDIGO study, digestive cancer patients with dynapenia experienced more chemotherapy-induced neurotoxicities. FIGHTDIGOTOX aimed to evaluate the…”
Get full text

Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients by Botsen, Damien, Ordan, Marie-Amélie, Barbe, Coralie, Mazza, Camille, Perrier, Marine, Moreau, Johanna, Brasseur, Mathilde, Renard, Yohann, Taillière, Barbara, Slimano, Florian, Bertin, Eric, Bouché, Olivier

“…FIGHTDIGO study showed the feasibility and acceptability of handgrip strength (HGS) measure in routine in 201 consecutive patients with digestive cancer…”
Get full text

Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis by Laures, Nicolas, Konecki, Céline, Brugel, Mathias, Giffard, Anne-Lise, Abdelli, Naceur, Botsen, Damien, Carlier, Claire, Gozalo, Claire, Feliu, Catherine, Slimano, Florian, Djerada, Zoubir, Bouché, Olivier

“…Dihydropyrimidine dehydrogenase (DPD) deficiency is associated with severe fluoropyrimidines-induced toxicity. As of September 2018, French recommendations…”
Get full text

Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC) by Le Bozec, Antoine, Brugel, Mathias, Djerada, Zoubir, Ayad, Marya, Perrier, Marine, Carlier, Claire, Botsen, Damien, Nazeyrollas, Pierre, Bouché, Olivier, Slimano, Florian

“…Preclinical studies have demonstrated the possible role of beta-adrenergic receptors in pancreatic ductal adenocarcinoma (PDAC) tumor invasion and migration…”
Get full text

Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy by Moreau, Johanna, Ordan, Marie‐Amélie, Barbe, Coralie, Mazza, Camille, Perrier, Marine, Botsen, Damien, Brasseur, Mathilde, Portefaix, Christophe, Renard, Yohann, Tallière, Barbara, Bertin, Eric, Hoeffel, Christine, Bouché, Olivier

“…Background FIGHTDIGO study has shown the feasibility of handgrip strength (HGS) measurements in 201 consecutive digestive cancer patients undergoing…”
Get full text

A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient by Gratiaux, Julian, Gossery, Chloé, Rezzag-Mahcene, Chirine, Botsen, Damien, Visseaux, Laetitia, Slimano, Florian, Bouche, Olivier

“…Introduction Capecitabine is an antimetabolite antineoplastic agent widely used in the treatment gastrointestinal cancers. The common frequently reported…”
Get full text

One‐year COVID‐19 outcomes on the oncology care patient pathway: Results of a French descriptive, cross‐sectional comprehensive study (ONCOCARE‐COV) by Laurent, Léonard, Brugel, Mathias, Carlier, Claire, Clere, Florentin, Bertrand, Aurélie, Botsen, Damien, Boulagnon‐Rombi, Camille, Dalstein, Véronique, Debreuve‐Theresette, Adeline, Deguelte, Sophie, Garbar, Christian, Mahmoudi, Rachid, Marechal, Antonin, Morland, David, Rey, Jean‐Baptiste, Schvartz, Claire, Vallet, Catherine, Merrouche, Yacine, Slimano, Florian, Bouché, Olivier

“…Background The COVID‐19 pandemic led to a widely documented disruption in cancer care pathway. Since a resurgence of the pandemic was expected after the first…”
Get full text

Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59 by Evrard, Camille, Aparicio, Thomas, Soularue, Emilie, Le Malicot, Karine, Desramé, Jérôme, Botsen, Damien, El Hajbi, Farid, Gonzalez, Daniel, Lepage, Come, Bouché, Olivier, Tougeron, David, On Behalf Of The Durigast-Prodige Investigators/Collaborators

“…Efficacy of immune checkpoint inhibitors (ICI) as monotherapy in 2nd line treatment for gastric or gastro-oesophageal junction (GEJ) adenocarcinoma is low,…”
Get full text

Preliminary guidelines for the detection and management of drug-related problems in cancer patients with type 2 diabetes mellitus: a practical resource for oncology pharmacists by Gossery, Chloé, Clarenne, Justine, Barraud, Sara, Brugel, Mathias, Boulin, Mathieu, Carlier, Claire, Perrier, Marine, Botsen, Damien, Hettler, Dominique, Kanagaratnam, Lukshe, Mongaret, Céline, Bouché, Olivier, Slimano, Florian

“…Purpose The prevalence of type 2 diabetes mellitus (T2DM) in cancer patients is high. During the medication review process, clinical pharmacists could detect…”
Get full text

Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France by Botsen, Damien, Lepoix, Elise, Mazza, Camille, Brasseur, Mathilde, Grange, Anne, Slimano, Florian, Bouché, Olivier

“…This study was undertaken to assess the previously unevaluated safety and feasibility of oxaliplatin-desensitization procedure add a French ambulatory cancer…”
Get full text

Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study by De La Fouchardière, Christelle, Malka, David, Cropet, Claire, Chabaud, Sylvie, Raimbourg, Judith, Botsen, Damien, Launay, Simon, Evesque, Ludovic, Vienot, Angélique, Perrier, Hervé, Jary, Marine, Rinaldi, Yves, Coutzac, Clélia, Bachet, Jean Baptiste, Neuzillet, Cindy, Williet, Nicolas, Desgrippes, Romain, Grainville, Thomas, Aparicio, Thomas, Peytier, Annie, Lecomte, Thierry, Roth, Gaël S, Thirot-Bidault, Anne, Lachaux, Nicolas, Bouché, Olivier, Ghiringhelli, François

“…GEMPAX was an open-label, randomized phase III clinical trial designed to assess the efficacy and tolerability of gemcitabine plus paclitaxel versus…”
Get full text

Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID) by Brugel, Mathias, Letrillart, Léa, Evrard, Camille, Thierry, Aurore, Tougeron, David, El Amrani, Mehdi, Piessen, Guillaume, Truant, Stéphanie, Turpin, Anthony, d'Engremont, Christelle, Roth, Gaël, Hautefeuille, Vincent, Regimbeau, Jean M., Williet, Nicolas, Schwarz, Lilian, Di Fiore, Frédéric, Borg, Christophe, Doussot, Alexandre, Lambert, Aurélien, Moulin, Valérie, Trelohan, Hélène, Bolliet, Marion, Topolscki, Amalia, Ayav, Ahmet, Lopez, Anthony, Botsen, Damien, Piardi, Tulio, Carlier, Claire, Bouché, Olivier

“…The COVID-19 pandemic caused major oncology care pathway disruption. The CAPANCOVID study aimed to evaluate the impact on pancreatic adenocarcinoma (PA) – from…”
Get full text

Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI) by Samalin, Emmanuelle, Senellart, Hélène, Evesque, Ludovic, Bouché, Olivier, Khemissa, Faiza, De La Fouchardiere, Christelle, Lopez, Anthony, Dermeche, Slimane, Botsen, Damien, Tougeron, David, Zaanan, Aziz, BEN Abdelghani, Meher, Guardiola, Emmanuel, Dubreuil, Olivier, Le Brun Ly, Valérie, Hennequin, Audrey, De Sousa Carvalho, Nicolas, Castan, Florence, Turpin, Anthony

“…387 Background: Several options have been evaluated as 2 nd line treatment in mGA after failure of 1 st line platinum based chemotherapy including taxanes and…”
Get full text

Feasibility of systematic handgrip strength testing in digestive cancer patients treated with chemotherapy: The FIGHTDIGO study by Ordan, Marie‐Amélie, Mazza, Camille, Barbe, Coralie, Perrier, Marine, Botsen, Damien, Renard, Yohann, Moreau, Johanna, Brasseur, Mathilde, Taillière, Barbara, Bertin, Éric, Bouché, Olivier

“…BACKGROUND Handgrip strength (HGS) is a widely studied noninvasive test. Weak strength (dynapenia) seems to be associated with high morbidity and mortality in…”
Get full text

Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial by Botsen, Damien, Chabaud, Sylvie, Perrier, Hervé, Ammarguellat, Hanifa, Jestin-Le-Tallec, Véronique, Olesinski, Jonathan, Toullec, Clémence, Aparicio, Thomas, Ben Abdelghani, Meher, Borg, Christophe, Bouche, Olivier, Coutzac, Clélia, Devaud, Hervé, Di Fiore, Frédéric, Dubreuil, Olivier, Evesque, Ludovic, Huguenin, Bruno, Muller, Marie, Poureau, Pierre-Guillaume, Oularue, Emilie, Tougeron, David, Zaanan, Aziz, Ammari, Samy, De Sousa Carvalho, Nicolas, Decazes, Pierre, De La Fouchardiere, Christelle

“…Trifluridine/tipiracil (FTD/TPI) is approved in third-line treatment of patients with advanced/metastatic gastric and gastroesophageal junction adenocarcinomas…”
Get full text

Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre observational cohort study (CAPANCOGEN) by Brugel, Mathias, Marulier, Thibault, Evrard, Camille, Carlier, Claire, Tougeron, David, Piessen, Guillaume, Truant, Stéphanie, Turpin, Anthony, Williet, Nicolas, Botsen, Damien, Brasseur, Mathilde, Perrier, Marine, Bouché, Olivier

“…Genetic counselling (GC) is a key step in the identification of inherited germline mutations. However, the oncogenetic practices are poorly described for…”
Get full text

FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study by Torregrosa, Cécile, Pernot, Simon, Vaflard, Pauline, Perret, Audrey, Tournigand, Christophe, Randrian, Violaine, Doat, Solene, Neuzillet, Cindy, Moulin, Valérie, Stouvenot, Morgane, Roth, Gael, Darbas, Tiffany, Auberger, Benjamin, Godet, Tiphaine, Jaffrelot, Marion, Lambert, Aurélien, Dubreuil, Olivier, Gluszak, Cassandre, Bernard‐Tessier, Alice, Turpin, Anthony, Palmieri, Lola‐Jade, Bouche, Olivier, Goujon, Gael, Lecomte, Thierry, Sefrioui, David, Locher, Christophe, Grados, Lucien, Gignoux, Pauline, Trager, Stéphanie, Nassif, Elise, Saint, Angélique, Hammel, Pascal, Lecaille, Cédric, Bureau, Mathilde, Perrier, Marine, Botsen, Damien, Bourgeois, Vincent, Taieb, Julien, Auclin, Edouard

“…After failure of first line FOLFOX‐bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second‐line FOLFIRI…”
Get full text

Association between pancreatic adenocarcinoma risk and concentration of organochlorine pesticides in adipose tissue and urine: A targeted‐screening analysis case‐control study (PESTIPAC) by Brugel, Mathias, Callon, Sidonie, Carlier, Claire, Amroun, Koceila Lamine, Botsen, Damien, Kianmanesh, Reza, Perrier, Marine, Piardi, Tullio, Renard, Yohann, Rhaiem, Rami, El Balkhi, Souleiman, Bouché, Olivier

“…Background Knowledge about environmental pancreatic adenocarcinoma (PA) risk factors, including pesticide exposure, remains limited. Organochlorine (OC)…”
Get full text